| 1 |
Matthay MA, Ware LB, Zimmerman GA.The acute respiratory distress syndrome [J].J Clin invest, 2012, 122(8): 2731-2740.
|
| 2 |
Ferguson ND, Fan E, Camporota L, et al.The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material [J].Intensive Care Med, 2012, 38(10): 1573-1582.
|
| 3 |
Thompson BT, Chambers RC, Liu KD.Acute respiratory distress syndrome [J].N Engl J Med, 2017, 377(6): 562-572.
|
| 4 |
Bos LDJ, Ware LB.Acute respiratory distress syndrome: causes,pathophysiology, and phenotypes [J].Lancet, 2022, 400(10358): 1145-1156.
|
| 5 |
Ashbaugh DG, Bigelow DB, Petty TL, et al.Acute respiratory distress in adults [J].Lancet, 1967, 2(7511): 319-323.
|
| 6 |
Murray JF, Matthay MA, Luce JM, et al.An expanded definition of the adult respiratory distress syndrome [J].Am Rev Respir Dis, 1988,138(3): 720-723.
|
| 7 |
Bernard GR, Artigas A, Brigham KL, et al.The American-European Consensus Conference on ARDS.Definitions, mechanisms, relevant outcomes, and clinical trial coordination [J].Am J Respir Crit Care Med, 1994, 149(3 Pt 1): 818-824.
|
| 8 |
ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al.Acute respiratory distress syndrome: the Berlin Definition [J].JAMA, 2012,307(23): 2526-2533.
|
| 9 |
Matthay MA, Arabi Y, Arroliga AC, et al.A new global definition of acute respiratory distress syndrome [J].Am J Respir Crit Care Med,2024, 209(1): 37-47.
|
| 10 |
Qadir N, Sahetya S, Munshi L, et al.An update on management of adult patients with acute respiratory distress syndrome: an Official American Thoracic Society Clinical Practice Guideline [J].Am J Respir Crit Care Med, 2024, 209(1): 24-36.
|
| 11 |
Qadir N, Bartz RR, Cooter ML, et al.Variation in early management practices in moderate-to severe ARDS in the United States: the Severe ARDS: generating evidence study [J].Chest, 2021, 160(4): 1304-1315.
|
| 12 |
Agarwal A, Hunt B, Stegemann M, et al.A living WHO guideline on drugs for COVID-19 [J].BMJ, 2020, 370: m3379.
|
| 13 |
Dequin PF, Meziani F, Quenot JP, et al.Hydrocortisone in severe communityacquired pneumonia [J].N Engl J Med, 2023, 388(21):1931-1941.
|
| 14 |
Chaudhuri D, Sasaki K, Karkar A, et al.Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis [J].Intensive Care Med, 2021, 47(5): 521-537.
|
| 15 |
Annane D, Sebille V, Bellissant E; Ger-Inf-05 Study Group.Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome [J].Crit Care Med, 2006,34(1): 22-30.
|
| 16 |
刘玲, 李佳, 黄英姿, 等.应激剂量糖皮质激素对合并危重病相关皮质醇不足的急性呼吸窘迫综合征患者的影响 [J].中华内科杂志,2012, 51(8): 5.
|
| 17 |
Meduri GU, Golden E, Freire AX, et al.Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial [J].Chest, 2007, 131(4): 954-963.
|
| 18 |
Meduri GU, Headley AS, Golden E, et al.Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial [J].JAMA, 1998, 280(2): 159-165.
|
| 19 |
Rezk NA, Ibrahim AM.Effects of methyl prednisolone in early ARDS[J].Egypt J Chest Dis Tuberc, 2013, 62: 167-172.
|
| 20 |
Steinberg KP, Hudson LD, Goodman RB, et al.Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome [J].N Engl J Med, 2006, 354(16): 1671-1684.
|
| 21 |
Tongyoo S, Permpikul C, Mongkolpun W, et al.Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome:results of a randomized controlled trial [J].Crit Care, 2016, 20(1): 329.
|
| 22 |
Villar J, Ferrando C, Martınez D, et al.Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomized controlled trial [J].Lancet Respir Med, 2020, 8(3): 267-276.
|
| 23 |
Horby P, Lim WS, Emberson JR, et al.Dexamethasone in hospitalized patients with COVID-19 - preliminary report [J].N Engl J Med, 2020,384: 693-704.
|
| 24 |
Jeronimo CMP, Farias MEL, Val FFA, et al.Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19): a randomized, double-blind, phase Ⅱb, placebocontrolled trial [J].Clin Infect Dis, 2021, 72(9): e373-e381.
|
| 25 |
Tomazini BM, Maia IS, Cavalcanti AB, et al.Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial [J].JAMA, 2020, 324(13): 1307-1316.
|
| 26 |
Dequin PF, Heming N, Meziani F, et al.Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial [J].JAMA, 2020, 324(13):1298-1306.
|
| 27 |
Angus DC, Derde L, Al-Beidh F, et al.Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial [J].JAMA, 2020, 324(13): 1317-1329.
|
| 28 |
Jamaati H, Hashemian SM, Farzanegan B, et al.No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomized clinical trial [J].Eur J Pharmacol,2021, 897: 173947.
|
| 29 |
宋志方, 应利君.糖皮质激素对急性呼吸窘迫综合征血管外肺水的影响 [J].中国急救医学, 2016, 36(5): 443-447.
|
| 30 |
周翔, 刘大为, 隆云, 等.俯卧位通气联合肺复张对重度急性呼吸窘迫综合征患者预后的影响 [J].中华内科杂志, 2014, 53(6): 437-441.
|
| 31 |
Jamaati H, Hashemian MR, Farzanegan B, et al.No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomized clinical trial [J].Eur J Pharmacol,2021, 897: 173947.
|
| 32 |
Tang BMP, Craig JC, Eslick GD, et al.Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis [J].Crit Care Med, 2009, 37(5): 2680-2681.
|
| 33 |
Ewald H, Raatz H, Boscacci R, et al.Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection [J].Cochrane Database Syst Rev, 2015, 2015(4): CD006150.
|
| 34 |
Tasaka S, Ohshimo S, Takeuchi M, et al.ARDS Clinical Practice Guideline Committee 2021 from the Japanese Respiratory Society, the Japanese Society of Intensive Care Medicine, and the Japanese Society of Respiratory Care Medicine.ARDS clinical practice guideline 2021[J].Respir Investig, 2022, 60(4): 446-495.
|
| 35 |
Munshi L, Brodie D, Fan E.Extracorporeal support for acute respiratory distress syndrome in adults [J].NEJM Evid, 2022, 1(10):EVIDra2200128.
|
| 36 |
Combes A, Peek GJ, Hajage D, et al.ECMO for severe ARDS:systematic review and individual patient data meta-analysis [J].Intensive Care Med, 2020, 46(11): 2048-2057.
|
| 37 |
Combes A, Hajage D, Capellier G, et al.Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome [J].N Engl J Med, 2018, 378(21): 1965-1975.
|
| 38 |
Peek GJ, Mugford M, Tiruvoipati R, et al.Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR):a multicentrerandomised controlled trial [J].Lancet, 2009, 374(9698):1351-1363.
|
| 39 |
Bellani G, Laffey JG, Pham T, et al; ESICM Trials Group.Epidemiology,patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries [J].JAMA, 2016, 315(8):788-800.
|
| 40 |
Slutsky AS.Neuromuscular blocking agents in ARDS [J].N Engl J Med, 2010, 363(12): 1176-1180.
|
| 41 |
Forel JM, Roch A, Marin V, et al.Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome [J].Crit Care Med, 2006, 34(11): 2749-2757.
|
| 42 |
Gainnier M, Roch A, Forel JM, et al.Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome [J].Crit Care Med, 2004, 32(1): 113-119.
|
| 43 |
Grasselli G, Calfee CS, Camporota L, et al; European Society of Intensive Care Medicine Taskforce on ARDS.ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies[J].Intensive care medicine, 2023, 49(7):727-759.
|
| 44 |
National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Moss M, Huang DT, et al.Early neuromuscular blockade in the acute respiratory distress syndrome [J].N Engl J Med, 2019,380(21): 1997-2008.
|
| 45 |
Tarazan N, Alshehri M, Sharif S, et al.Neuromuscular blocking agents in acute respiratory distress syndrome: updated systematic review and meta analysis of randomized trials [J].Intensive Care Med, 2020, 8(1): 61.
|
| 46 |
Guervilly C, Bisbal M, Forel JM, et al.Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome [J].Intensive Care Med, 2017, 43(3): 408-418.
|
| 47 |
Papazian L, Forel JM, Gacouin A, et al.Neuromuscular blockers in early acute respiratory distress syndrome [J].N Engl J Med, 2010,363(12): 1107-1116.
|
| 48 |
吕光宇, 王晓源, 蒋文芳, 等.早期应用神经肌肉阻断剂治疗严重脓毒症合并急性呼吸窘迫综合征的临床研究 [J].中华危重病急救医学, 2014, 26(5): 325-329.
|
| 49 |
Fanelli V, Morita Y, Cappello P, et al.Neuromuscular blocking agent cisatracurium attenuates lung injury by inhibition of nicotinic acetylcholine receptor-α1 [J].Anesthesiology, 2016, 124(1): 132-140.
|
| 50 |
Sottile PD, Albers D, Moss MM.Neuromuscular blockade is associated with the attenuation of biomarkers of epithelial and endothelial injury in patients with moderate-to-severe acute respiratory distress syndrome [J].Crit Care, 2018, 22(1): 63.
|
| 51 |
Dianti J, Tisminetzky M, Ferreyro BL, et al.Association of positive end-expiratory pressure and lung recruitment selection strategies with mortality in acute respiratory distress syndrome: a systematic review and network meta-analysis [J].Am J Respir Crit Care Med, 2022,205(11): 1300-1310.
|
| 52 |
Brower RG, Lanken PN, MacIntyre N, et al.Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome [J].N Engl J Med, 2004, 351(4): 327-336.
|
| 53 |
Mercat A, Richard JC, Vielle B, et al.Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial [J].JAMA, 2008, 299(6): 646-655.
|
| 54 |
Pintado MC, de Pablo R, Trascasa M, et al.Individualized PEEP setting in subjects with ARDS: a randomized controlled pilot study [J].Respir Care, 2013, 58(9): 1416-1423.
|
| 55 |
Gorman EA, O’Kane CM, McAuley DF.Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management [J].Lancet, 2022, 400(10358): 1157-1170.
|
| 56 |
Griffiths MJD, McAuley DF, Perkins GD, et al.Guidelines on the management of acute respiratory distress syndrome [J].BMJ Open Respir Res, 2019, 6(1): e000420.
|
| 57 |
Papazian L, Aubron C, Brochard L, et al.Formal guidelines:management of acute respiratory distress syndrome [J].Ann Intensive Care, 2019, 9(1): 69.
|
| 58 |
Briel M, Meade M, Mercat A, et al.Higher vs lower positive endexpiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis [J].JAMA, 2010, 303(9): 865-873.
|